[Pre-Aug 2018] IMSCAR
- Published
Orphan drugs revisited: author's response.
Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351Research output: Contribution to journal › Article › peer-review
- Published
The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol
Hughes, D., Jenkinson, M. D., Gamble, C., Hartley, J. C., Hickey, H., Hughes, D. A., Blundell, M., Griffiths, M. J., Solomon, T. & Malluci, C. L., 3 Jan 2014, In: Trials. 15, 14Research output: Contribution to journal › Article › peer-review
- Published
Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?
Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Aug 2007.Research output: Contribution to conference › Paper
- Published
Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.
Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8Research output: Contribution to journal › Article › peer-review
- Published
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.Research output: Contribution to conference › Paper
- Published
Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Charitable contributions to funding cancer services for children and young people in England and Wales
Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2008, In: Journal of Child Health Care. 12, 2, p. 156-168Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial
Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.Research output: Contribution to conference › Paper
- Published
Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.
Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.Research output: Contribution to conference › Paper
- Published
Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence
Hughes, D., Plumpton, C. O., Brown, I., Reuber, M., Marson, A. G. & Hughes, D. A., 26 Mar 2015, In: Epilepsy and Behavior. 45, p. 180-186Research output: Contribution to journal › Article › peer-review
- Published
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.
Hughes, D., Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., Van Eker, D., Stevens, L., Hawkins, K., Toh, C. H., Kamali, F., Daly, A. K., Fitzmaurice, D., Coffey, A., Williamson, P. R., Park, B. K., Deloukas, P. & Pirmohamed, M., 1 Oct 2009, In: Pharmacogenetics and Genomics. 19, 10, p. 800-812Research output: Contribution to journal › Article › peer-review
- Published
Pharmacokinetics, patient compliance and pharmaeconomics
Hughes, D. & Hughes, D. A., 1 Jun 2005.Research output: Contribution to conference › Paper
- Published
From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics
Hughes, D. & Hughes, D. A., 1 May 2002.Research output: Contribution to conference › Paper
- Published
Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.
Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Patient compliance and pharmacoeconomics
Hughes, D. & Hughes, D. A., 1 Oct 2001.Research output: Contribution to conference › Paper
- Published
Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial
Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Mar 2007.Research output: Contribution to conference › Paper
- Published
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.
Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Oct 2001, In: Health Economics. 10, 7, p. 601-615Research output: Contribution to journal › Article › peer-review
- Published
The development of a QALY measure for epilepsy: NEWQOL-6D
Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 May 2012, In: Epilepsy and Behavior. 24, 1, p. 36-43Research output: Contribution to journal › Article › peer-review
- Published
Pharmacoeconomics appraisals by the all Wales medicines strategy group
Hughes, D. & Hughes, D. A., 1 Jul 2004.Research output: Contribution to conference › Paper
- Published
Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.
Hughes, D. & Hughes, D. A., 1 Jul 2005, In: European Journal of Cancer. 41, 11, p. 1655Research output: Contribution to journal › Article › peer-review
- Published
The difference between effectiveness and efficacy of antimalarial drugs in Kenya.
Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Sept 2004, In: Tropical Medicine and International Health. 9, 9, p. 967-974Research output: Contribution to journal › Article › peer-review
- Published
Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance
Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.Research output: Contribution to conference › Paper
- Published
Introduction to pharmaeconomics
Hughes, D. & Hughes, D. A., 1 Jul 2004.Research output: Contribution to conference › Paper
- Published
An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes
Hughes, D., Farmer, A., Hardeman, W., Hughes, D. A., Prevost, A. T., Kim, Y., Craven, A., Oke, J., Boase, S., Selwood, M., Kellar, I., Graffy, J., Griffin, S., Sutton, S. & Kinmonth, A. L., 5 Apr 2012, In: BMC Family Practice. 13, 30Research output: Contribution to journal › Article › peer-review
- Published
Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.
Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 May 2009, In: Pharmacoeconomics. 27, 8, p. 635-643Research output: Contribution to journal › Article › peer-review
- Published
A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands
Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Nov 2004.Research output: Contribution to conference › Paper
- Published
Defining rewardable innovation in drug therapy
Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Apr 2012, In: Nature Reviews Drug Discovery. 11, p. 253-254Research output: Contribution to journal › Article › peer-review
- Published
Statistical comments are unfounded.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346Research output: Contribution to journal › Article › peer-review
- Published
The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.Research output: Contribution to conference › Paper
- Published
Pharmacoeconomics of pharmacogenetic testing: azathioprine
Hughes, D., McAllister, R. & Hughes, D. A., 1 Apr 2004.Research output: Contribution to conference › Paper
- Published
A systematic review and empirical analysis of the relation between dose and duration of drug action.
Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Mar 2010, In: Clinical Pharmacology and Therapeutics. 87, 3, p. 257-261Research output: Contribution to journal › Article › peer-review
- Published
Orphan drug treatments: economic considerations
Hughes, D. & Hughes, D. A., 1 Nov 2007.Research output: Contribution to conference › Paper
- Published
Welsh Health Economics Network (WHEN): Scoping Report.
Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions
Hughes, D., Roberts, E., Dawoud, D. M., Hughes, D. A. & Cefai, C., 1 Oct 2015, In: International Journal of Pharmacy Practice. 23, 5, p. 333-339Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Nov 2005.Research output: Contribution to conference › Paper
- Published
Integrating compliance and persistence in health economics models
Hughes, D. & Hughes, D. A., 1 Jan 2008.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Impact of non-compliance on the cost-effectiveness of statin therapy
Hughes, D., Hughes, D. A. & Bagust, A., 1 Sept 2001, In: Value in Health. 4, 6, p. 489Research output: Contribution to journal › Article › peer-review
- Published
Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.
Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
The future challenges
Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 167-174Research output: Chapter in Book/Report/Conference proceeding › Chapter
- Published
Engaging with the MRC Methodology Hubs – NWHTMR.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Economic impact of poor compliance with pharmaceuticals.
Hughes, D. & Hughes, D. A., 1 Aug 2002, In: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, p. 327-335Research output: Contribution to journal › Article › peer-review
- Published
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009, p. O41.Research output: Contribution to conference › Paper
- Published
Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.
Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Public meetings of the NICE appraisals committee
Hughes, D. & Hughes, D. A., 1 Dec 2007.Research output: Contribution to conference › Paper
- Published
Pharmacoeconomic models that incorporate non-compliance
Hughes, D. & Hughes, D. A., 1 Jul 2004.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment
Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.Research output: Contribution to conference › Paper
- Published
Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?
Hughes, D. & Hughes, D. A., 1 Nov 2006.Research output: Contribution to conference › Paper
- Published
Quantitative risk-benefit analysis
Hughes, D. & Hughes, D. A., 1 May 2007.Research output: Contribution to conference › Paper
- Published
The pharmacokinetic profile of Warfarn: a systematic review
Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Dec 2007.Research output: Contribution to conference › Paper
- Published
Warfarin pharmacogenetics: Economic considerations.
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Jan 2007, In: Pharmacoeconomics. 25, 11, p. 899-902Research output: Contribution to journal › Article › peer-review
- Published
Use of PK-PD modelling to predict the impact of non-compliance
Hughes, D. & Hughes, D. A., 1 Nov 2003.Research output: Contribution to conference › Paper
- Published
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Multiple imputation of multiple multi-item scales when a full imputation model is infeasible
Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Jan 2016, In: BMC Research Notes. 9, 45, p. 1-15Research output: Contribution to journal › Article › peer-review
- Published
Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.
Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2005, 2005 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Aug 2007, In: Clinical Pharmacology and Therapeutics. 82, 2, p. 123-127Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design
Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.
Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836Research output: Contribution to journal › Article › peer-review
- Published
Adverse drug reactions in economic evaluations
Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109Research output: Contribution to journal › Article › peer-review
- Published
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Jun 2004, In: Pharmacogenetics. 14, 6, p. 335-342Research output: Contribution to journal › Article › peer-review
- Published
Methodological issues in the literature on costs of non-compliance in chronic diseases
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.Research output: Contribution to conference › Paper
- Published
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Oct 2011, In: British Medical Journal. 343, p. 1-14Research output: Contribution to journal › Article › peer-review
- Published
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749Research output: Contribution to journal › Article › peer-review
- Published
Pharmacogenetic tests: the need for a level playing field
Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Jan 2013, In: Nature Reviews Drug Discovery. 12, 3-4Research output: Contribution to journal › Article › peer-review
- Published
Drug compliance and pharmaceconomics
Hughes, D. & Hughes, D. A., 1 Dec 2003.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Economic evaluation during early (phase II) trials
Hughes, D. & Hughes, D. A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis
Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 May 2007.Research output: Contribution to conference › Paper
- Published
Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.
Hughes, D., Hughes, D. A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 11, p. 1069-1077Research output: Contribution to journal › Article › peer-review
- Published
A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)
Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, N. V., 9 Jan 2014, In: Trials. 15, 14Research output: Contribution to journal › Article › peer-review
- Published
Abolition of prescription copayments in Wales: an observational study on dispensing rates.
Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Aug 2010, In: Value in Health. 13, 5, p. 675-680Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Effects of the abolition of prescription charges in Wales: A preliminary analysis
Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.Research output: Contribution to conference › Paper
- Published
Impact of the abolition of the prescription charge in Wales
Hughes, D. & Hughes, D. A., 1 Nov 2008.Research output: Contribution to conference › Paper
- Published
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Nov 2007, In: Value in Health. 10, 6, p. 498-509Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
A prototype agent-based model of antimalarial drug compliance
Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Aug 2007.Research output: Contribution to conference › Paper
- Published
Back to basics: what is the relationship between dose and duration of drug action?
Hughes, D. & Hughes, D. A., 1 May 2006.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.
Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Mar 2012, In: Pharmacoeconomics.Research output: Contribution to journal › Article › peer-review
- Published
What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?
Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 May 2007.Research output: Contribution to conference › Paper
- Published
Is exercise effective in promoting mental well-being in older age? A systematic review.
Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Aug 2010, In: Aging and Mental Health. 14, 6, p. 652-669Research output: Contribution to journal › Article › peer-review
- Published
Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Sept 2012, In: Pharmacogenomics. 13, 12, p. 1405-1417Research output: Contribution to journal › Article › peer-review
- Published
The problem of orphan drugs
Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Nov 2010, In: British Medical Journal. 341, p. 335-341Research output: Contribution to journal › Article › peer-review